Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ultibro

- PMLiVE

Novartis and Precision BioSciences announce in vivo gene editing collaboration

The companies will work together to develop potentially curative treatments for disorders including sickle cell disease and beta thalassaemia

dengue fever mosquito

Novartis endorses Kigali Declaration by investing $250m for tropical diseases

1.7 billion people suffer from neglected tropical diseases worldwide, and there are 241 million cases of malaria

- PMLiVE

MSD and AstraZeneca announce phase 3 results for prostate cancer therapy

The results show that the Lynparza combination therapy significantly improved radiographic progression-free survival

- PMLiVE

Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine

Almost all children involved with copies of the SMN2 gene treated pre-symptomatically met key milestones

- PMLiVE

Novartis announces promising five-year data for leukaemia treatment Kymriah

Results have shown durable remission and long-term survival in children and young adults with B-cell acute lymphoblastic leukaemia

- PMLiVE

CureVac to acquire Frame Cancer Therapeutics in €32m deal

The acquisition will advance CureVac’s oncology strategy and offers the potential to develop off-the-shelf and personalised cancer vaccines

- PMLiVE

FDA approves GSK’s Priorix vaccine for measles, mumps and rubella

The vaccine has been approved to use in those aged 12 months and above

Part 3 of the Medscape video series #EHA

Ahead of  Europe’s largest hematology conference Hansa Bhargava MD, Medscape Education Chief Medical Officer, interviews Dr. Naval Daver on the most important abstracts to look out for in Myeloid and...

Medscape Education Global

Part 2 of the Medscape video interview series

Ahead of Europe’s largest haematology conference Hansa Bhargava MD, Medscape Education Chief Medical Officer interviews Dr. John Gribben on the most important abstracts to look out for in CLL and the...

Medscape Education Global

- PMLiVE

Novartis’ Kymriah receives FDA approval to treat follicular lymphoma

The CAR-T cell treatment is approved for adult patients who have had two or more previous therapies

- PMLiVE

Phase 3 trial initiated to evaluate AZ’s Saphnelo in lupus nephritis

The antibody has already been approved to treat systemic lupus erythematosus

- PMLiVE

Results released from new study of AstraZeneca’s COVID-19 antibody

A new study from Oxford University shows that Evusheld is effective in protecting against emerging Omicron variants

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links